Efficacy of photodynamic therapy and intravitreal injection of ranibizumab in patients with polypoidal choroidal vasculopathy
10.3760/cma.j.issn.1005-1015.2016.01.008
- VernacularTitle:单纯光动力疗法与玻璃体腔注射雷珠单抗以及两者联合治疗息肉样脉络膜血管病变疗效比较
- Author:
Yanhua LIANG
;
Yanping SONG
;
Qin DING
;
Zhongshan CHEN
- Publication Type:Journal Article
- Keywords:
Choroid diseases/therapy;
Angiogenesis inhibitors/therapeutic use;
Antibodies,monoclonal/therapeutic use;
Photochemotherapy;
Comparative effectiveness research
- From:
Chinese Journal of Ocular Fundus Diseases
2016;32(1):31-35
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy of photodynamic therapy (PDT) alone or in combined with ranibizumab versus ranibizumab monotherapy (intravitreal injection,IVR) in patients with polypoidal choroidal vasculopathy (PCV).Methods 80 eyes of 72 patients with PCV were enrolled into this retrospective and comparative study according to their therapeutic plan.30 eyes of 28 patients,28 eyes of 30 patients and 22 eyes of 21 patients were divided into PDT group,ranibizumab 0.5 mg group (IVR group) or the combination group,respectively.The patients with PCV were diagnosed according to clinical symptoms,optical coherence tomography (OCT) and fluorescent indocyanine green angiography (ICGA).The baseline best-corrected visual acuity (BCVA) before treatment was more than 0.05,and there was no retinal fibrosis and scar for all patients.There was no statistical difference of age (F=0.187),gender (x2 =0.423),average BCVA (F=1.120) and central retinal thickness (CRT) (F=0.431) among three groups (P＞0.05).They had not received any treatment before.Patients received verteporfin PDT in PDT group,3 consecutive monthly IVRs starting day 1 in IVR group,and 3 IVRs after 3 days,1 month,2 months of PDT starting day 1 in combination group.Re-treatment was considered 3 months later if the follow up shown no changes in fundus photography,OCT and ICGA.The average follow-up time was 19 months.BCVA at baseline and follow-up visit at 1,3,6,12 months was measured,and the proportion of patients with ICGA-assessed complete regression of polyps at month 6 was recorded as primary outcome.The CRT was measured at baseline and 6 months as secondary outcome.Results There were significant difference of BCVA at 1,3,6 and 12 months among three groups(F=5.480,5.249,3.222,4.711;P＜0.05).The average BCVA was significantly better at 1,3,6,12 month than that at baseline(t =-6.632,-4.127,-3.904,-4.494;P＜ 0.05) in combination group,and was significantly better at 3,6,12 months than that at baseline (t=-5.636,-3.039,-3.833;P＜0.05) in IVR group.However there was no significant difference of the average BCVA in PDT group between follow-up at 1,3,6,l 2 months and baseline (t=1.973,0.102,-0.100,-0.761;P＞0.05).The proportion of patients with complete regression of polyps at 6 months was higher in PDT (76.7％) or combination group (68.2％) than IVR group (35.7％) (x2=0.003,0.025;P＜0.05).There was no significant difference of CRT among 3 groups at baseline (P=0.651).The mean CRT decreased in all 3 treatment groups over 6 months (t=5.120,3.635,5.253;P＜0.05),but there was no significant difference of CRT among 3 groups (F=1.293,P＞ 0.05).Conclusions Three therapies could effectively decrease CRT.IVR or IVR combined with PDT are both more effective than PDT therapy to improve vision of PCV patients.PDT or PDT combined with IVR was superior to IVR pnly in achieving complete regression of polyps in 6 months in PCV patients.
